Pre-made Eldelumab benchmark antibody ( Whole mAb, anti-CXCL10 therapeutic antibody, Anti-C7/IFI10/INP10/IP-10/SCYB10/crg-2/gIP-10/mob-1 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Eldelumab biosimilar, Whole mAb, Anti-CXCL10 Antibody: Anti-C7/IFI10/INP10/IP-10/SCYB10/crg-2/gIP-10/mob-1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Eldelumab (alternative identifier BMS-936557[1]) is a fully human monoclonal antibody (type IgG1 kappa)[2] that targets chemokine (C-X-C motif) ligand 10 (CXCL10)/Interferon-γ-inducible protein-10 (IP-10)[2][1] designed for the treatment of Crohn's disease and ulcerative colitis.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-168-1mg	1mg	3090	30%	2163

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Eldelumab biosimilar, Whole mAb, Anti-CXCL10 Antibody: Anti-C7/IFI10/INP10/IP-10/SCYB10/crg-2/gIP-10/mob-1 therapeutic antibody
INN Name	Eldelumab
Target	CXCL10
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2013
Year Recommended	2014
Companies	Bristol-Myers Squibb;Medarex
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Crohn's disease;Ulcerative colitis;Multiple sclerosis;Rheumatoid arthritis;Spinal cord injuries
Development Tech	Medarex UltiMAb Mouse